MindMed earnings

The psychedelics-focused medicines company MindMed (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), announced its second-quarter financial results Friday with a net and comprehensive loss of $36 million, which compares to a loss of $14 million in the previous quarter. Net...

Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) confirmed Friday it will commence trading on the Nasdaq Capital Market under the ticker symbol “MNMD” on April 27th. The psychedelic medicine biotech company reported its subordinate voting shares have obtained the necessary...